Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for ...

Author(s)

Gourzoulidis G1, Koulentaki M1, Koumarianou A2, Samantas E3, Androulakis N4, Xynogalos S5, Papakotoulas P6, Boukovinas I7, Karamouzis M8, Souglakos I9, Chotzagiannoglou V10, Beletsi A11, Kourlaba G1
1Econcare LP, Athens, A1, Greece, 2Fourth Department of Internal Medicine Attikon University Hospital, Athens, Greece, 3Medical Oncology, "METROPOLITAN" Hospital, Piraeus, Greece, 4Medical Oncology Unit, Pananio-Venizelio General Hospital of Heraklion, Heraklion, Greece, 5Medical Oncology, "Metaxas" Cancer Hospital, Piraeus, Greece, 6First Department of Clinical Oncology, Theagenio Hospital, Thessaloniki, Greece, 7Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece, 8School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 9Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece, 10Servier Hellas Pharmaceuticals Ltd, Athens, Greece, 11Servier Hellas Pharmaceuticals Ltd, Athens, A1, Greece

OBJECTIVES : To estimate the budgetary impact from the introduction of trifluridine/tipiracil (FTD/TPI) as a third-line treatment option for patients with metastatic gastric cancer(mGC), including adenocarcinoma of the gastroesophageal junction(GEJ), among patients who have received at least two prior therapies for metastatic disease in Greece.

METHODS : A budget impact model was developed from a public payer perspective over a 5-year time horizon to estimate the financial impact of FTD/TPI by taking market shares from available treatments options in Greece. Based on local experts, patients with mGC are currently treated with irinotecan, nivolumab, ramucirumab and pembrolizumab, which represents common clinical practice in the absence of any other recommendation. The model framework considered market share scenarios with and without FTD/TPI and reimbursed costs of treatment applied to the eligible Greek patient population. The number of eligible patients was estimated using data from published literature and local experts. The projected uptake of FTD/TPI was provided by Servier. Drug acquisition and drug administration cost of treatments were considered in the analysis and were retrieved from the Greek Ministry of Health. The model-measured outcome was incremental budget impact from the introduction of FTD/TPI as a third-line treatment option in patients with mGC.

RESULTS : Over the 5-year horizon, the total number of the eligible population was 209 patients per year and the number of Greek patients who received FTD/TPI was 21, 63, 84, 105, 105 in the years 1 to 5, respectively. The annual incremental cost associated with the introduction of FΤD/ΤPI was €11,728, €35,184, €46,912, €58,639, and €58,639 for years 1 to 5 respectively, resulting in a total 5-year budget impact of €211,102.

CONCLUSIONS : In addition to the clinical benefits, the introduction of FTD/TPI as a third-line treatment option for patients with mGC was predicted to be associated with a limited budget increase for the payer.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PCN57

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×